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Abstract 
Human immunodeficiency virus (HIV) utilizes our immune system to replicate in the 
body while having developed ways to evade it. However, immune cells have intrinsic 
barriers against HTV. Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 
(APOBEC), most notably APOBEC3G (A3G) and APOBEC3F (A3F) are cytidine 
deaminases that act by mutating deoxycytidine (dC) to deoxyuridine (dU) in the(-) strand 
DNA that is generated upon reverse transcription of the viral genome. A3G/F are 
constitutively expressed pre-infection with HTV and act non-specifically throughout the 
viral DNA. For these reasons, they are considered anti-viral host restriction agents that 
pa1ticipate in the initial innate immune response against HTV. Adaptive immunity is a 
more specific immune response that carries an immunological memory, and in the case of 
HIV, consists of anti-viral antibodies as well as cytotoxic CDS+ T cells (CTL). Here, we 
hypothesize that beyond A3G/F role in innate immunity within infected cells, mutations 
by A3G/F modulate HTV recognition by the adaptive immune system through modifying 
peptide epitopes recognized by CTL. To test our hypothesis, we I) identified all CTL 
epitopes restricted to each human leukocyte antigen (HLA) in silica, 2) identified the 
CTL epitopes and A3G/F hotspots therein that are mutable by A3G/F and simulated 
mutat ions in them, 3) measured the CTL responses of HLA-matched, HIV -infected 
individuals to peptides containing A3G/F mutations ex vivo, and 4) analyzed the 
frequencies of A3G/F hotspot motifs inside and outside of the CTL epitopes in silica. Our 
results reveal for the first time that rather than being beneficial fo r the adaptive immune 
system, mutations of the HIV genome by A3G/F may have the opposite effect by assisting 
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HlV to escape from CTL responses. Furthermore, we show that the HlV genome has 
adapted to position A3G/F hotspot motifs selectively in CTL epitopes to maximally 
subvert the action of A3G/F towards immune escape. 
3 
Appendix 1 
Acknowledgment 
I wish to express my sincere to my supervisor Dr. Mani Larijani and my co-supervisor Dr. 
Michael Grant for providing me this opportunity to complete my M.Sc. I am also thankful 
for their advice, facilities and funding during my research . I also would like to thank my 
committee member Dr. Ken Hirasawa. Financial support was provided by Memorial 
University and CIHR. 
4 
Abstract 
Acknowledgments 
List ofTables 
List of figures 
HTV -infected cohort status table 
Abbreviations 
Chapter I: Introduction 
Co-authorsh ip statement 
Appendix 2 
Table of contents 
2-3 
4 
6 
6 
7- 10 
11-12 
13-21 
22 
Chapter 2: Emerging complexities of APOBEC3G action on immunity and viral fitness 
during HIV infection and treatment 
Chapter 3: Positioning of APOBEC3G!F mutational hotspots favors reduced 
recognition ofHTV by CDS+ T cells 
Summary 
Bibliography 
23-42 
43-71 
72-75 
76-95 
5 
Appendix 3 
List of Tables 
Chapter 3: 
Table 1. List of wild type and A3G/F-mutated epitopes used to measure the CD8+ T cel ls 
response of HLA -matched HIV -infected individuals. 67 
Table 2. Analyzing enrichment of A3G/F hotspot inside/outside CTL epitopes in HIV 
genes. 6S 
List of Figures 
Chapter 1: 
Figure 1. Structure of HIV -I 21 
Chapter 2: 
Figure 1. The complexities of the pro- and anti-HIV actions of AP08EC3G 41 
Chapter 3: 
Figure 1. Delineation ofthe amino acid and DNA sequences ofCTLepitopes. 61 
Figure 2. Simulation of A3G/F-mediated mutations ofCTL epitopes. 62 
Figure 3. The response of CDS+ T cells from different HIV -infected individuals to HLA-
857-restricted wild type and A3G/F -mutated epitopes. 63 
Figure 4. The response of CDS+ T cells from different HIV -infected individuals to HLA-
A2-restricted wi ld type and A3G/F-mutated epitopes. 64 
Figure 5. The response of CDS+ T cells from different HIV-infected individuals to HLA-
844-restricted wild type and A3G/F-mutated epitopes. 65 
Figure 6. Analyzing enrichment of A3G/F hotspot inside/outs ide CTL epitopes in HTV 
genes. 66 
6 
Appendix 4 
HIV-infected cohort status table 
Patient Viral HLA 
ID load 
1 1.6- A1,A2;813,B18 
5.49 
3 1.6- A1,A2;B8,844 
4.9 
7 1.6- A2,844;Bw57 
5.6 
17 1.7- A3,A25;87,B44 
4.48 
18 1.7- A2,A29;844,Bw6 
6.21 
20 1.7- A1,All;Bw57,Bw75 
5.5 
21 1.7- A2;Bw60,Bw62 
5.78 
26 1.6- A2,A26;B8,Bw55 
4.75 
27 1.6- A2,A3;87,827 
4.84 
30 1.6- A2,All;B7,Bw62 
4 .53 
35 1.6- A2,A30;813,844 
4 .77 
44 1.6- A2,All;B44 
4 .67 
45 1.6- A1,A2;844,Bw57 
4 .37 
46 1.6- A1,A3;Bw53,Bw57 
5.35 
50 1.6- A2,A3;835,BW67 
5.45 
51 1.6- A24,Aw34;835,841 
5.7 
55 1.7- All,A28;844,851 
5.14 
57 1.6- A3,A29;87,844 
4.95 
60 4.57- A2,A3;827,BW60 
5.88 
61 1.6 A3,A23;849,851 
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62 1.6-4 A2;B7,Bw60 
63 2.01- A9;B18,B44 
5 .61 
64 1.6- A2,A32;B44 
3 .7 
67 1.6- A24,A29;B44,B48 
5.67 
68 2.7- A2,A29;Bw57,Bw62 
4.41 
69 1.7- A3,A28;B7,B8 
3 .18 
70 1.7- A1,A2;B7,B44 
5.41 
71 1.6- A1,A2;B18,Bw57 
4 .37 
75 1.7- A3,A24;B7,B44 
5 .28 
76 1.7- A1,A9;B57,B49 
4 .83 
77 2.1-5 A1,A3;B8,B44 
78 1.69- Al,A29;B18,Bw41 
5.88 
79 1.6- A24,Aw34;Bl4,B35 
2.6 
81 1.7- A2;B7,Bw61 
5.72 
82 1.6- A3,A24;B7,B35 
5.57 
84 1.6- A3,All;B7, B35 
4.59 
90 1.6- A2;B56, Bw62 
6.22 
98 1.6- A1,A2;B8,B49 
5 .73 
103 1.6- A1;B8,B44 
4.9 
105 1.6- A2,A3;B7,B13 
5 .88 
109 1.7- A2;B39 
2.46 
115 1.6- A1,A2; B44, Bw60 
2.6 
117 1.6- A2,A3;B7,B44 
5.25 
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119 1.6- Al,A2;B8,Bw60 
2.6 
123 1.7- Al,A2;B8,Bw58 
2.71 
124 1.6-5 A3,A32;B7,B51 
125 1.6- A2,A27;B14,B44 
4.68 
132 1.7- A2;Bw62 
5.69 
133 1.7-5 Al,A24;B37,B44 
134 1.6-2 A2,All;B44,B35 
135 1.7 A2,A30;B13,Bw50 
136 1.7- All;B44,BS1 
5.04 
138 1.6- A3,A28;Bw62 
1.7 
143 1.6- A26,A29;B38,B44 
4.77 
148 1.6- Al,A2;B8,B35 
5.59 
149 0- Al,A2;Bw57,Bw61 
5 .67 
151 1.6- A2,A24;B13,B35 
5.88 
153 1.6- A2,A29; B44, Bw62 
5.13 
166 1.6- A2,All;B57,B49 
5.88 
168 A2,A3;B15,B35 
179 1.66- Al,A2;B7,B35 
5 .88 
181 1.7- Al,A2;B27,BSS 
4.79 
184 Al,A25;B44,BS2 
193 1.6- A2,A25;B44,B62 
2.6 
196 1.6- A2,All;B7,B13 
1.7 
197 1.6-3 A2,A28;B15,B57 
200 1.6- A3,A24;B39,B18 
5 .88 
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201 1.6- A2,A3;B7,B40 
4.94 
203 1.6- A28,A29;B44 
5.88 
209 1.6- A3,All;B14,B40 
6.2 
210 1.6- A2;B40,B44 
4.67 
211 1.6- A2,A24;B40,B44 
5 .06 
213 1.6- A2,A24;B51,B60 
4.83 
214 1-1.7 A2,A31;B40,B44 
216 1.6- A2,A24;B50,B62 
1.7 
219 1.6- A11,A28;B14,Bw4,Bw6 
5.03 
224 1.6- A1,A3;B8,B18,Bw6 
5.02 
231 1.6- A2;B14,Bw27,Bw4,Bw6 
4.87 
233 1.7- A2,A24;B18,B44,Bw4,Bw6 
4.19 
234 0-5.8 A2,A24;Bw4,B18,B44 
237 1.6 A2;B27,Bw4 
242 1.78- A2,A24;B44,B55 
4.98 
244 3 .81- A2,A24;B7,B35,Bw48 
6.3 
246 3.12 A3;B18,B35,B44,Bw48 
247 1.6 A11,A24;B35,B52,Bw48 
249 A1,A2; 827,851 
250 4.89 A2;B27;Bw48 
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Abbreviation 
Ab 
AID 
AIDS 
AP 
APOBEC 
CTL 
DC 
ELISA 
FCS 
HIV 
HMM 
HLA 
ISED 
LMM 
NK cells 
NCBI 
PBMC 
PBS 
PCR 
PRR 
RPMI 
Full name 
antibody 
Appendix 5 
Abbreviation 
activation induced deaminase 
acquired immunodeficiency syndrom 
alkaline phosphatase 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide 
cytotoxic T lymphocyte 
dendritic cells 
enzyme-linked immunosorbent assay 
fetal calf serum 
human immunodeficiency virus 
high molecular mass 
human leukocyte antigen 
influenza sequence & epitope database 
low molecular mass 
natural killer cells 
national center for biotechnology information 
peripheral blood mononuclear cells 
phosphate buffer saline 
polymerase chain reaction 
pattern recognition receptor 
roswell Park Memorial Institute medium 
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RT 
SFC 
SIV 
TLR 
TRIM 
reverse transcriptase 
spot forming cells 
simian immunodeficiency virus 
toll- like receptor 
tripartite motifs 
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Chapter 1 
Introduction to retroviruses 
Human immunodeficiency vi rus (HIY) is a lentivirus that belongs to the 
retroviridae family of viruses. Infection by HIY eventually causes acquired 
immunodeficiency syndrome (AIDS), a fatal disease characterized by weak immune 
system that was first discovered in 1981 [I]. The structure of a typical member of the 
retroviridae family is composed of genomic RNA in addition to Gag, Pol, and Env 
proteins that, after further processing, form other structural and functional proteins [2]. 
Some genes have been expanded in recently evolved members of this group, such as 
lentiviruses which encode for accessory proteins including Yif, Ypr, Ypu, Tat, Rev, and 
Nef whose main functions are to regulate replication, processing, gene expression, and 
assembly of viruses. HIY is a well-known member of this group discovered in 1983 by 
PCR (polymerase chain reaction) [2-4]. Another member of this group is simian 
immunodeficiency virus (SlY), which infects different primates but mainly Asian 
macaques. It has been suggested that cross-species transmission has caused progressive 
development of SlY into HIY [5]. There are two sub-types of HIY: HIY-1 and HIY-2. 
These two are different in structural and functional properties and cause immune 
responses that have distinct characteristics and require different therapeutic strategies [6, 
7]. HIY -I is the more popular and common type of the virus, having infected more than 
40 million people worldwide [6]. Its structure is composed of a lipoprotein membrane that 
surrounds 72 glycoprotein complexes embedded in a lipid membrane including 
glycoprotein gp 120 and a transmembrane protein gp41. Two other proteins (p 17 and p24) 
surround and encapsulate the viral genome. HIY -I genomic nucleic acid complex (Fig. I) 
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is composed of RNA, nucleoprotein, reverse transcriptase (RT), integrase and a protease 
[8] . 
The life cycle of HIV 
The HIV life cycle starts primari ly with viral fusion to susceptible cells by binding 
the gp 120 protein to CD4 on the target cells surface by non-covalent binding that leads to 
activation of co-receptors (CCR5 and CXCR4) on the ~ell surface and aids viral fusion to 
the target cell. This causes injection of a v iral core complex into the host cell cytoplasm 
which is followed by viral un-coating in order to free the two copies of the HIV genomic 
RNA. HIV replicates in the infected cells by reverse transcription that generates double-
stranded blunt-ended DNA (dsDNA) from single-stranded viral RNA [9, 4]. This process 
is catalyzed by v iral reverse transcriptase (RT) complex that is composed of RT and a 
cellular tRNA31ys. TRNA3lys is used as primer to initiate reverse transcription [I 0]. 
Reverse transcriptase complex mediates the synthesis of a minus sense ssDNA template 
from the viral RNA. This complex also contains RNAase H activity to c leave RNA after 
form ation of ssDNA and is used as a polymerase to generate double stranded DNA 
(dsDNA) from reverse transcribed ssDNA [10] . The dsDNA form of the v ira l genome is 
translocated to the nucleus and integrates into host chromosomal DNA by the integrase 
enzyme [II]. HIV utilizes host replication factors to express viral proteins that integrate 
into the budding virions with viral genomic RNA [II] . After further post- translational 
modifications and processing, proteins such as enzymes are assembled into vi ral particles. 
[12] . These assembled v irions are infectious and possess the abi lity to infect other target 
cells. 
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HIV target cells, co-receptors, and pathogenesis 
After primary infection by HIV, high level of virus in the body triggers the 
immune response. The asymptomatic stage of the disease may take several years during 
which the host immune system maintains low levels of the virus. The high cytotoxic 
activity of HIV enables it to destroy immune cells leading to the symptomatic phase of 
the disease and progression to AIDS [I]. One reason underlying reason for the effect of 
HIV on immune cells is that the key receptor for HIV is the CD4 surface marker on these 
cells [ 13]. HIV infects distinct cell types including HIV specific CD4+ T cells that are 
differentiating from naive to mature phenotypes. Moreover, HIV is able to rep I icate in 
differentiated monocytes, dendritic cells (DC) with up-regulated cell markers, and also in 
activated macrophages [ 14-16]. These cells represent the main antigen-presenting cells of 
the immune system and induce specific immune responses against antigens. The 
importance ofDCs, macrophages, and monocytes in HIV infection is mainly because they 
capture HIV and mediate its transmission to CD4+ T cells and prolong HIV infection in 
the host [17]. CCRS and CXCR4, the main co-receptors for HIV infect ion, are necessary 
for the interaction of the HTV - I envelope glycoprotein gp 120 with CD4 during binding of 
HIV to monocytes/macrophage-tropic and T -cell tropic HIV - I viruses [ 13, 18]. Infection 
of CD4+ T cells by HIV cause a decline in cell number and cell markers. Fas-mediated 
apoptosis of infected cells, CD8+ cytotoxic T lymphocyte (CTL)-mediated destruction of 
infected cells, and down-regulation ofCD4 co-stimulatory molecule on T cel l surface [13, 
19-21 ]. The final clinical outcome of these processes is that the depletion of CD4+ T cells 
in blood results in AIDS that increases the chance of opportunistic infections and tumors 
that are surmountable by a healthy immune system [22]. 
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Innate immunity against HIV 
After infection of susceptible cells by HIV, the immune response against the virus 
is activated. As with all infections, the initial response against HJV is through the innate 
immune pathways. Toll-like receptors (TLRs) are an important part of the innate immune 
response that belong to pattern recognition receptors (PRR) family and recognize specific 
motif in pathogens [23]. TLR 7/8 are important for HJV integration and are activated 
through the recognition of viral uridine-rich RNA [23]. TLR7/8 are mainly expressed in 
DCs and natural killer (NK) cells and lead to activation of immune pathways in these 
cells [24]. Interaction with pathogens activates these receptors and triggers a cell 
signaling cascade in the target cell. These cellular pathways induce or suppress the 
expression of genes that lead to inflammatory responses against the pathogen. After 
engagement of PRR by viral antigens, pro-inflammatory responses such as NF-KB and 
JFN are triggered in target cells [24]. This results in the production of cytokines and 
chemokines that are required to trigger other intracellular antiviral pathways, recruit 
immune cells to the site of infection and prime the adaptive immune response [24]. 
Intrinsic immunity against HIV 
There is another layer of innate immunity against HIV that is caused by cellular 
factors including tripartite motifs (TRIM), tetherin, and apol ipoprotein B mRNA-editing, 
enzyme-catalytic polypeptide-3 (APOBEC3) family members that belong to intrinsic 
immunity [27, 28, 29]. These host-restriction factors are the very first lines of defense 
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against HlV after its entry into target cells and are constitutively present in the target 
cells. TRIM are cellular proteins that have antiviral functions [27]. Different members of 
the TRIM family including Rhesus TRIMS and TRIM 1 affect viral uncovering by 
targeting capsid (CA) viral protein which then envelops the viral core complex and 
inhibits early or late viral replication [27]. TRIM22 and TRIM28 are other members of 
the family that interrupt viral reverse transcription and transcription processes [30, 31]. 
Another intracellular protein that restricts HIV infection is tetherin, which is a trans-
membrane protein with an abnormal folding. It functions by changing into protease-
sensitive tethers that retains viral particles on host cell membranes and inhibits their 
entrance to the target cells [28]. 
APOBEC3 family enzymes, especially A3G/F, are cytidine deaminases that act by 
substituting dC to dU in the negative strand of the viral genome during its replication in 
the cytoplasm of infected T cells. These mutations can lead to the degradation of viral 
DNA by uracil removal pathways, or alternatively result in dG to dA mutations in the 
coding (positive) strand which potentially incapacitate the coding ability of the viral 
genome [29, 32]. A3G/F have also been suggested to target HIV through deaminase 
independent mechanisms involving the physical binding of the enzyme to the viral 
genome and restriction of viral reverse transcription process, or restriction of integration 
into the host genome [29, 33]. 
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A3G restricting factors and purifying selection 
A3G is a kinetically rapid enzyme that has the capacity to induce tens to hundreds 
of mutations per viral replication [34]. Despite the theoretically high potential of mutation 
induction by A3G, there are a number of A3G restricting factors that limit its activity. For 
example, A3G is targeted for destruction by the virion infectivity factor (Vit) protein of 
HIV. It has been proposed that the level at which A3G edits the viral genome is partially 
controlled by the virus through Vif action [35-38]. It is possible that Vif is a regulatory 
factor that has evolved to control the induced rate of mutations in order to allow HIV to 
better adapt itself to external pressures [36]. In addition, entrapment of A3GIF in high 
molecular mass (HMM) complexes, composed of many different types of cellular 
proteins and RNA, limits the pool of active cytoplasmic A3G/F [40]. Also, after inducing 
mutations into the viral genome, other elements, such as DNA repair mechanisms, filter 
out some of these mutations induced within the HIV DNA sequence. [n addition, viral 
sequences with high levels of mutations are sequentially eliminated as more fit viruses are 
selected for, at each progressive stage of the viral life cycle . This inherent selection for 
more fit and less mutated viruses throughout the viral lifecycle has been referred to as 
"purifying selection" [39]. Consequently, the numbers of the mutations persisting in the 
viral genome which are transmitted to the next viral generations are only a fraction ofthe 
initial level of mutations that A3G may have introduced in the parental viral genome. 
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Adaptive immunity against HIV 
Following the initial innate immune restriction, adaptive immune response in the 
long term controls HIV replication. This task is mainly carried out by cytotoxic CD8+ T-
cells (CTL) and also by neutralizing antibodies [ 41]. CD8+ T-cells recognize a complex 
of antigens and human leukocyte antigen (HLA) class I molecules on antigen-presenting 
cells. Various HLA types induce different levels of CTL response and are associated with 
slow versus fast disease progression [42). HIY-specific CD8+ T-cells secrete perforin and 
granzymes A and B which mediate the cytolysis effect [43]. In addition to their 
cytotoxicity effect, they enhance the immune response by releasing IFN-y and TNF-a/~ 
[44]. During adaptive immune response, infected CD4+ T-cells that are the main target of 
HIV will be killed by CD8+ T-cells. Depletion ofCD4+ T-cells and suppression of their 
generation leads to acute lymphopenia that causes AIDS progression. 
Immune evasion by HIV 
HfV is a highly mutation-tolerant virus with the abil ity to adapt to external 
pressures [45]. These pressures include antiviral drugs as well as the host immune system. 
The effect of mutations in the viral genome to escape from drug treatment and the 
immune response has been reported [46]. One of the mechanisms used by HfV to evade 
host immunity is through interruption of the CTL response [47), which can be caused by 
mutations in CTL epitopes [ 48-51 ]. Evolution of viral escape mutations inside epitopes is 
dependent on each individual type of HLA. For example, patients with HLA associated 
high CTL response develop specific CTL escape mutations in viral genome. These 
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mutations may impair viral replication and reduce viral load in the host. However, if this 
virus infects other individuals with different type of HLA and less immune pressure, the 
original genotype is regained that forms a fully replicative and competent virus [ I , 52). 
Hypothesis: 
We hypothesize that beyond A3G/F recognized role in innate immunity, low level 
non-deactivating A3G/F-induced mutations modulate adaptive immunity by modifying 
peptide epitopes recognized by cytotoxic T cells. The following sections will discuss the 
dual role of APOBEC family member enzymes in HIV restriction and evolution (chapter 
1 ). Experimental ex vivo and in silica data that support a prominent role for A3G/F 
induced mutations in the modulation of adaptive anti-viral immunity as well as in the 
evolution of the viral genomic sequence will be presented in chapter 2. 
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gp41 
gp120 
Lipid 
bilayer 
P17 matrix antigen 
P24 core antigen 
Reverse transcriptase 
Integ rase 
Figure 1. Structure of HIV-1. A lipid membrane including glycoprotein gp120 and a transmembrane 
protein gp41 surround HIV complex that are shown by the green circle and blue/brown hexagons. Pl7 and 
p24 proteins encapsulate the viral genome that are denoted by a brown circle and black hexagon. HIV -1 
genomic nucleic acid complex is composed of RNA, nucleoprotein, reverse transcriptase (RT), integrase 
and protease that are represented by a black line and red/brown circles. 
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Chapter 2 
Emerging complexities of APOBEC3G action on immunity and viral fitness during 
HIV infection and treatment 
Mahdis Monajemi 1t, Claire F Woodworth2t, Jessica Benkaroun2, Michael Grane· and 
Mani Larijani3* 
Abstract 
The enzyme APOBEC3G (A3G) mutates the human immunodeficiency virus (HIV) 
genome by converting deoxycytidine (dC) to deoxyuridine (dU) on minus strand viral 
DNA during reverse transcription. A3G restricts viral propagation by degrading or 
incapacitating the coding ability of the HIV genome. Thus, this enzyme has been 
perceived as an innate immune barrier to viral replication whilst adaptive immunity 
responses escalate to effective levels. The discovery of A3G less than a decade ago led to 
the promise of new anti-viral therapies based on manipulation of its cellular expression 
and/or activity. The rationale for therapeutic approaches has been solidified by 
demonstration of the effectiveness of A3G in diminishing viral replication in cell culture 
systems of HIV infection, reports of its mutational footprint in virions from patients, and 
recognition of its unusually robust enzymatic potential in biochemical studies in vitro. 
Despite its effectiveness in various experimental systems, numerous recent studies have 
shown that the ability of A3G to combat HIV in the physiological sett ing is severely 
limited. In fact, it has become apparent that its mutational act ivity may actually enhance 
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viral fitness by accelerating H IV evolution towards the evasion of both anti-viral drugs 
and the immune system. This body of work suggests that the role of A3G in HIV 
infection is more complex than heretofore appreciated and supports the hypothesis that 
HIV has evolved to exploit the action of this host factor. Here, we present an overview of 
recent data that bring to light historical overestimation of A3G's standing as a strictly 
anti-viral agent. We discuss the limitations of experimental systems used to assess its 
activities, as well as caveats in data interpretation. 
The role of APOBEC3G in HIV restriction 
APOBEC3G (A3G) is a recently discovered primate-specific member of the 
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like editing complex 
family of cytidine deaminase enzymes with potential to inhibit propagation of the HIV 
[I ,2]. Eleven members of the APOBEC family are found in humans and includes 
activation-induced cytidine deaminase (AID), APOBEC I, APOBEC2, APOBEC3A-H, 
and APOBEC4 [3 ,4]. These enzymes convert deoxycytidine (dC) to deoxyuridine (dU) in 
single stranded DNA (ssDNA) or RNA of human and viral genomes, thereby affecting a 
variety of physiological functions [5- 7]. A3G was discovered through the study of 
heterokaryons generated between cells permissive and non-permissive to infection by 
virion infectivity factor (Vif)-deficient HIV that were used to determine the action ofthe 
HIV protein Vif [1,8,9]. A3G is primarily expressed in CD4+ T lymphocytes, 
macrophages, and dendritic cells, which are all the natural targets of HIV infection [2, I 0-
14], although expression in other tissues may be induced by interferon(s) [15- 18]. A3G 
mutates dC in nascent viral minus strand DNA generated by reverse transcription [ 17- 24] 
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and preferentially deaminates dC in signature trinucleotides (CCC, TCC) often referred to 
as hotspots [6, 19-2 1]. The resulting dUs can trigger DNA degradation through the action 
of DNA repair pathways, such as those involving uracil DNA glycosylase and apurinic-
apyrimidinic endonuclease [25,26]. For viral genomes that evade destruction, the 
consequent deoxyguanosine (dG) to deoxyadenosine (dA) substitutions in plus strand 
DNA can alter reading frames, introduce premature translation termination codons, and/or 
produce mutated viral proteins [7,20-25]. In addition, A3G can disrupt propagation of 
HIV by binding viral RNA, interfering with the DNA strand transfer acrobatics of reverse 
transcription, physically blocking reverse transcriptase (RT), and obstructing integration 
into the host cell genome [24,26-31]. A3G has been shown to block RT activity by 
decreasing tRNA priming, competing for bind ing to templates, restricting strand transfer 
during reverse transcription, and direct binding [28,32,33]. Beyond the reverse 
transcription stage, incorporation of dU into minus strand DNA of the HlV genome has 
been shown to interfere with synthesis of the complementary plus strand [23]. These 
findings initially led to the notion that A3G can inhibit viral propagation through 
pathways dependent or independent of its deamination activity. However, many studies 
supporting deaminase-independent activities utilized A3G overexpression. It has recently 
been appreciated that with low level A3G expression, which may be a more accurate 
representation of the physiological case, deaminase activity is requ ired for viral restriction 
[34-39]. While the relative contribution of deamination independent activities to viral 
restriction remains contentious, these may prove more relevant to the action of A3G in 
restricting endogenous non-long terminal repeat retrotransposons, such as long and short 
interspersed nuclear elements [ 40--45]. The anti-retroelement activity of A3G may 
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represent a host strategy to protect its genome from the deleterious effects of transposable 
elements. A possible mechanism could involve the binding of A3G to retroelements 
resulting in blockage oftheir mobility [46] . 
The recent expansion of a single APOBEC3 gene in mice to seven (APOBEC3A-
H) in primates and the relatively high divergence within APOBEC3 enzymes in primates 
are evidence for immense evolutionary pressure on the locus suggested to possibly be 
concomitant with the emergence of modern lentiviruses [3,4,47,48]. Conversely, the 
finding that the accelerated rate of A3G divergence predates modern lentiviruses, together 
with the lack of a clear correlation between human A3G polymorphisms and the 
progression of acquired immunodeficiency syndrome (AIDS), suggest that lentiviral 
pressure may be, at best, only partially responsible for expansion of the APOBEC3 locus 
[49-52]. This manner of growth in host defence capacity can reciprocally drive co-
evolution of highly adaptable viruses. In this regard, we highlight an emerging body of 
evidence suggesting that the activity of A3G may be partially subverted by HIV for its 
survival benefit. These data support a more complex scenario in which the initial 
perception of A3G as a strictly anti-viral agent may have been na'lve. 
Viral and cellular factors limiting APOBEC3G effectiveness 
The view of A3G as a potent intrinsic anti-viral factor was largely borne out of 
findings of high levels of dG to dA hypermutated virus sequences in di- and tri-nucleotide 
motifs targeted by A3G [53- 57]. In stark contrast, the previously recognized mutational 
machinery of HIV, RT, only introduces approximately one mutation per viral genome 
during a replication cycle [58]. Supporting the potency of A3G as a mutagen ic agent is a 
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wealth of biochemical data showing that it is a highly processive enzyme able to mediate 
multiple mutations on a given stretch of ssDNA. Accordingly, A3G significantly 
diminishes viral propagation in several cell culture experimental systems of HIV infection 
[7,20,22,42,4 7]. 
To counteract these activities, lentiviruses have evolved several strategies, 
primarily in the form of auxiliary proteins such as Yif, which binds and targets newly 
synthesized A3G for degradation via an ubiquitin-dependent proteosomal pathway [59-
69]. A3G is packaged into virions in infected virus-producing cells and it has been shown 
that it is largely this virion-packaged fraction of A3G rather than the pool of cytoplasmic 
A3G that is most active on the viral genome in newly infected cells [70-74]. The number 
of A3G molecules incorporated into each virion is dependent on the level of A3G 
expression in the producer cell [75] . On average, 3 to II molecules of A3G are sufficient 
for effective viral restriction in the target cell [76]. Besides lowering A3G levels through 
degradation, Yif has also been suggested to directly interfere with A3G encapsidation and 
may impair its translation [66, 74, 77-80]. Yif utilizes other co-factors present in the target 
cell to ubiquitinate A3G and it was recently shown that Core binding factor (CBF)-~, a 
cellular transcription factor, is required for Yif-mediated degradation of A3G [81 ,82]. As 
a result, when Yif is present, the mutation levels induced by A3G and its effectiveness in 
viral restriction are diminished. 
That Yif is essential for HIV replication in A3G expressing cells, and that the sole 
function of Yif was thought to be A3G inactivation, lent credence to the notion that A3G 
is a potent restrictor of HIV propagation [83] . On the other hand, it is now appreciated 
that even in the presence of Yif, A3G can sti ll cause sub-lethal levels of dG to dA 
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mutations [19,84]. It is possible that the preferential targeting of newly synthesized A3G 
by Vif leaves a fraction of previously synthesized A3G intact [85]. In addition, it appears 
that Vif expression does not completely abolish A3G activity and the correlation between 
the levels of viral infectivity and A3G inhibition by Vif is not absolute [62,78]. Other 
functions for Vif and Vif mediated ubiquitination, besides A3G degradation, are also 
coming to light. For instance, along with the auxiliary protein Vpr, Vif can induce G2 
cell-cycle arrest, which may contribute to CD4+ T lymphocyte depletion [86-89]. Vif 
thus mediates several functions that are independent of its interaction with A3G and is a 
variable negative regulator of A3G activity rather than a complete inhibitor. 
A3G action is further limited by its entrapment in high-molecular-mass 
ribonuclear complexes (HMM) that may reach mega daltons in size, med iated by non-
specific binding of cellular and/or viral RNA and proteins [12,7 1 ,90-97]. The shuttling of 
A3G into newly synthesized virions depends on binding viral RNA and/or proteins [98-
101]. The requirement for high affinity interactions with RNA/DNA substrates may 
explain the evolution of A3G (and other APOBEC enzymes, e.g. AID) to contain an 
unusually high number of charged residues on its surface [I 02-1 04]. Ironically, this same 
attribute, necessary to enact the anti-viral function of A3G, may also be a key contributor 
to limiting its antiviral function through HMM formation. Reversion of HMM to low-
molecular-mass (LMM) A3G can be experimentally mediated by treatment with RNase 
A/H [70,71, 105] . The RNase H activity of RT is thought to release viral RNA-bound 
A3G, allowing it to act on the proximal minus strand DNA during its synthesis [2, 19,75]. 
Enzymatically active A3G able to be incorporated into newly synthesized virions is 
strictly found outside of the HMM complexes in the LMM fraction [73, I 06]. The LMM 
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form primarily resides in peripheral blood-derived resting CD4+ T cells and monocytes 
[12). However, upon activation of CD4+ T cells or differentiation of monocytes into 
macrophages, a higher proportion of A3G is shuttled to HMM complexes [2,91 ]. 
Although this was suggested to be a mechanism that restricted the infection of resting T 
cells by HIV, subsequent knockout studies of LMM A3G in resting CD4+ T cells did not 
render these cells permissive to HIV infection, thus indicating that the difference in the 
LMM versus HMM-bound proportion of A3G is not the sole mechanism for resistance of 
resting CD4+ T cells to HIV infection [I 07, I 08]. Beyond the induction of HMM 
formation by HIV through cellular activation processes, Vif has been shown to di rectly 
promote HMM production [I 09). Remarkably complex co-evolution is evident 
considering the intimate linkage between HIV infect ion and HMM formation and the 
notable level of mechani stic integration between A3G function and the viral replication 
machinery. The RNase H activity of RT is at once both necessary and detrimental to viral 
propagation due to its role in the release of active A3G. 
The complexities surrounding regulation of Vif activity and HMM formation 
notwithstanding, it is clear that both result in dim inished A3G efficacy. It is possible that 
mutations introduced by A3G only succeed in restricting viral replication at a sub-optimal 
level and conversely may assist the virus by generating sequence variation [35,39,84]. 
Consequently, an alternative view that A3G activity can contribute to viral fitness has 
recently gained strong support. In the following sections, we highl ight ev idence fo r the 
pro-viral activities of A3G. At the same time, we discuss caveats of experimental systems 
and data interpretation that must henceforth be considered in development of a revised 
and better-informed picture of A3G function. 
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The role of APOBEC3G in generation of anti-viral drug resistant HIV 
Gain of resistance to drug(s) used in the treatment of HIV is a major determ inant 
of viral evolution during the course of disease. To date, almost a hundred drug resistance 
mutation sites have been identified in the HIV genome [II 0]. These induce resistance to 
common anti-HIV drugs acting as nucleoside/nucleotide analogue RT inhibitors, such as 
2',3'-dideoxy-3'-thiacytidine (3TC), abacav ir (ABC), and 2',3 '-dideoxyinosine (DDI), as 
well as non-nucleoside/nucleotide analogue RT inhibitors, including Nev irapine (NVP), 
Delavirdine (DLV), and Efavirenz (EFV) [ I I 0]. Drug resistance mutations function 
directly by altering drug targets or indirectly by modify ing pathways that contribute to 
drug escape. Many drug resistance mutations have been shown to reside in A3G hotspots 
[Ill] . 
A bioinformatics study assessed the probability of A3G mutations in known drug 
resistance sites taking into consideration the double-crested gradient of A3G induced 
mutational levels throughout the HIV genome. Out of 52,000 G to A mutations, only 695 
( 1.3%) were located in drug resistance sites [ 11 2]. In thi s context, the investigators 
reported a modest correlation between A3G activity and the generation of drug resistance 
mutations relative to the overall footprint of A3G on the HIV genome [ 19, 11 2, 113]; 
however, recent experimental ev idence more strongly implicates A3G in the generation of 
drug resistance mutations. For example, the very common M 1841 (V) mutat ion of RT that 
causes resistance to 3TC and, to a lesser extent, ABC and DDI, is located in an A3G 
hotspot (TCCAT to TCUAT) and is produced by A3G in vitro during HIV replication in 
cell culture systems [I 14]. Intriguingly, this was observed in the absence of 3TC in as 
many as 40% of sequenced prov iruses, reflecting a pre-treatment pool of resistant viruses 
30 
poised for propagation after drug exposure [29, 115-118]. Because this mutation may in 
fact reduce viral replication fitness in the absence of3TC [119-122], it is likely that this 
measurement actually underestimates the role of A3G in the generation of this mutation. 
In support of this notion, the M 1841 mutation emerges at significantly higher rates when 
the virus is grown in A3G-expressing as compared to A3G non-expressing host cells, 
indicating that A3G activity is the major source of this mutation [ 123]. This is a striking 
example of the parallel role of A3G in simultaneously aiding host and virus: in the same 
manner that it acts as a pre-existing innate immune factor that fortifies host defenses prior 
to viral exposure, A3G boosts the inherent ability of HIV to gain resistance even before 
drug treatment. That this mutation is associated with a decline in viral fitness may 
indicate that drug resistance presents a significant source of pressure in viral evolution 
resulting in the gain or maintenance of A3G hotspots in key positions in the viral genome. 
If the contribution of A3G action to drug resistance and survival of H1V is a 
biologically considerable one, the evolution of HIV during disease could involve active 
relaxation of A3G inhibition. Indeed, direct evidence for this phenomenon was provided 
by the prevalence of the Vif K22H mutation in patients failing drug treatment, as 
compared to treatment-na'ive patients [ 124, 125]. Vif K22 is a key residue for interaction 
with A3G, and Vif K22H exhibits reduced effectiveness in neutralizing A3G [115]. Ex 
vivo infection of peripheral blood mononuclear cells (PBMCs) with viral stocks harboring 
various other Vif mutations that are unable to deactivate A3G (e.g. Vif K22E) yielded a 
significant increase in the generation of M 1841 mutants [ 114]. In addition, several drug 
resistance mutations, including M 1841 in RT and G 16E/M361 in the protease, are 
significantly more common in patients harbouring elevated relative levels of K22H-
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mutated viruses [125] . Like the M1841 mutation, both G16E and M361 mutation sites are 
located in A3G hotspots. Thus, not only does HIV benefit from spontaneous pre-drug 
treatment A3G induced mutations in a passive, somewhat random manner, it appears that 
resistance sites for some of the most commonly used drugs arose in A3G hotspots. This in 
no way implies viral sentience, but merely indicates a selective advantage derived from 
the overlap of sites more susceptible to mutation (A3G hotspots) being able to confer 
drug resistance. 
The contribution of APOBEC3G to the evasion of adaptive immunity by HIV 
Restrictions imposed on the activity of A3G by Vif and HMM limit its 
effectiveness as an innate immune agent. However, follow ing the first weeks of HIV 
infection, development of B and T cell mediated adaptive immunity partially controls 
viremia [ 116-118, 126]. A central facet of the adaptive immune response is elimination of 
infected target cells by cytotoxic T cells (CTL), as highlighted by the close inverse 
association between robustness of the CTL response with viremia levels and disease 
progression [1 27- 129]. Thus, evasion of the CTL response is thought to be a powerful 
driving force for the evolution of HIV during disease, as confirmed by several studies 
showing the prevalence of CTL escape in H IV infection [ 130,13 I]. CTL evasion may 
result from alterations in CTL access to infected cells. For instance, the auxiliary HIV 
protein Nef modulates class I MHC expression to decrease the recognition and killing of 
infected cells [ 132]. Alternatively, CTL evasion may result from alterations in the 
interactions between the CTL and infected target cel l. Mutations in CTL recogn ition 
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epitopes have been shown to mediate CTL evasion through modulating the efficacy of 
CTLactivation [133- 135]. 
It is possible that HIV can exploit the limited non-lethal action of A3G to generate 
CTL escape mutants. In support of this model, a study examining CTL escape during 
early infection found that approximately a third of the rapidly mutating sites mediating 
CTL escape were embedded in A3G hotspots, with more highly mutat ing sites being 
relatively enriched in A3G hotspots [ 136]. Twenty-four rapidly diversifying sites were 
identified at which G to A mutations were 2-3 fold more frequent than the overall G to A 
mutation rate across the entire HIV genome (29 versus 12%). Fourteen ofthese sites were 
located in or near CTL epitopes. These data suggest that it may be advantageous towards 
immune escape for HIV to maintain A3G hotspots in areas where mutations can affect 
processing, presentation or recognition ofT cell epitopes, or conversely to establish T cell 
epitopes near A3G hotspots. 
In contrast, another study reported that A3G mutations enhance the virus-specific 
CTL response through the introduction of premature stop codons into the HIV genome 
that cause the generation of truncated or misfolded proteins [1 37]. In this study, Yif+ or 
Yif- HIV was produced in the presence or absence of A3G in a cell line and subsequently 
used to infect PBMCs followed by assessing their susceptibil ity to MHC-matched peptide 
specific CTL clones. It is possible that the finding of enhanced target cell killing as a 
result of A3G activity reflects an inherent bias of the specificity of the CTL clones 
examined. In addition, given the numbers, diversity, and relative scarcity of CTL specific 
for each particular peptide in vivo, the general biological relevance of this work remains 
to be determined. Therefore, although A3G appears to play a role beyond innate 
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immunity and modulate adaptive immunity, further work is required to elucidate the 
nature and extent of this activity. 
Manipulation of APOBEC3G effectiveness: implications and challenges for the 
design of therapeutic approaches 
To date, multiple avenues have been suggested and/or pursued towards 
exploitation of A3G as an antiviral therapy. These approaches include the development of 
small molecules that inhibit the interaction between Yif and A3G and/or inhibit 
interactions with cellu lar factors that act downstream of Yif, enhancement of LMM 
formation over HMM formation, and increasing A3G levels by treatment with interferons 
or gene-therapy delivery of A3G along with the restriction factor Trim Sa [70, 138- 140]. 
Strategies to down-regulate the action of Yif and HMM that were initially suggested as 
therapeutic approaches have recently been questioned in light of the increasingly apparent 
pro-viral activities of A3G [35, 141 ]. Disturb ing the Yif-APOBEC interaction presents a 
delicate challenge because subtle adjustments to Vif activity have been shown to 
modulate levels of A3G activity. For instance, naturally occurring patient-derived virions 
harbouring Yif mutations selectively exhibit vi ral genome sequence variations consistent 
with survival advantage under their environmental pressures [25,54, 125]. Incomplete Yif 
inhibition might increase effective A3G concentrations and in so doing actual ly accelerate 
viral evolution by only modestly increasing non-lethal mutation rates [22, Il l]. On the 
other hand, complete Vif inhibition may result in A3G activ ity levels high enough to tip 
the balance towards immunity through mutation loads capable of disabling viral 
replication. The isolation of viral sequences harboring Yif mutants significantly 
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diminished in their ability to neutralize A3G challenges this scenario as it brings into 
question the ability of A3G to fully abrogate the propagation of Yif-deficient viruses 
[ 124, 125]. Furthermore, it may also be important to consider the involvement of Yif 
inactivation in the generation of drug resistance as a cautionary note against therapies 
designed for complete elimination ofVifactivity. 
Studies of the effect of A3G expression levels on HIV disease progression rates in 
both humans and other primates have yielded conflicting results. One investigation 
reported an inverse correlation between A3G expression levels and disease progression 
[142, 143], whi le another noted no such association [144] . A third study conducted on 
SlY -infected rhesus macaques reported an inverse correlation between A3G expression 
levels and disease progression [ 145]. Further work will be required to conclusively define 
any association between A3G expression patterns or levels and H IV disease progression. 
In addition, it is not clear whether A3G expression levels can influence the relative extent 
of its pro- versus anti-viral activities. 
If indeed there is any correlation, it remains to be determined where the threshold 
level of A3G activity lies and whether it varies during the course of infection. Whatever 
the pivotal point, the underlying premise that regulating A3G activity by modulating 
Yif/HMMs can alter viral mutation levels to the detriment of HIV may be flawed in 
viewing HIV as an acqu iescent canvas for mutational activity. Examination of the 
spectrum of A3G induced mutations during the viral li fe cycle paints a different picture in 
which there is a high level of mutation in viral DNA, an intermediate level in cellular 
RNA, and a low level in viral RNA. Non-advantageous or detrimental mutations are 
serially fi ltered out during the transcription, nuclear-cytoplasmic transport, translation and 
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assembly phases of the viral life cycle, resulting in a pool of virions emerging from the 
host cell that bear a suppressed footprint of total A3G mutational activity, a process 
termed purifying selection [ 146]. Although at first glance it ought to decrease viral 
variation, purifying selection is balanced in favour of H IV by other diversification 
processes, such as recombination between mutated and wild-type viral genomes 
[ 14 7, 148]. This is a sophisticated mechanism of protection for the virus as it enhances the 
potential for beneficial mutations to propagate quickly and represents a heretofore 
unappreciated layer of complexity when considering therapeutic strategies centered 
around modulating the activity and/or levels of A3G. 
The relative contribution of APOBEC3G in the context of other viral factors to HIV 
evolution 
Formulating therapeutic strategies also requires a careful assessment of the 
relative contributions of non-A3G factors to the sequence variation of HIV. In general, 
retroviral genomes are prone to a high frequency of mutation [149-153]. The elevated 
error rate of the HIV RT, alterations in the nucleoside triphosphate (NTP) and 
deoxynucleotide triphosphate (dNTP) levels that affect polymerase accuracies, and the 
lack of proofreading machinery during viral genome replication all contribute to the 
highly mutagenic nature of viral genomes [58, 151]. In addition to mutations, HIV 
exhibits a notably high rate of genom ic recombination amongst retroviruses, possibly due 
to its cellular transmission properties resulting in frequent co-infection by genetic variants 
[ 154- 157]. Unlike in humans, recombination in retroviruses does not result from 
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breakage and rejoining of DNA, but is instead mediated by the ability of RT to switch 
templates between the two encapsidated proviral RNAs [158-160]. 
Distinguishing between the actions of RT versus A3G is essential in determining 
the relative contribution of each to HIV pathogenesis given that its genome is 
predominated by dA nucleotides, and dG to dA changes are key to the generation of many 
drug resistance variants [Ill, 161 , 162]. Prior to the discovery of A3G, RT was viewed as 
the main generator of genetic diversification in the HIV genome throughout the course of 
infection; however, both RT and A3G most frequently induce dG to dA transition 
mutations on the plus viral DNA strand [ 163]. Although a degree of uncertainty arises in 
assigning the source of hypermutations in the HIV genome, the fact that A3G 
preferentially deaminates dC nucleotides in signature trinucleotide hotspots (CCC, TCC) 
can be used to assign mutations [6, 19- 21]. In contrast to RT, which is capable of 
introducing one to two mutations in each viral genome per replication cycle [58], A3G is 
a highly processive and robust deaminase enzyme [164]. The rate of dG to dA 
hypermutation found in HIV genomes is approximately I 000 fold higher than RT alone 
would be expected to introduce [71 ]. Furthermore, A3G expressing cells support 
significantly more HIV hypermutation than their A3G-deficient counterparts. While the 
impact of A3G on mutational load is tempered during wild-type HIV infection by factors 
such as Yif and HMM, and potentially obscured from the circulating virus pool by 
purifying selection, these and other observations provide evidence that A3G can and does 
make substantial contributions to HIV sequence variation [ 123]. Somewhere between the 
unfettered A3G activity that causes a lethal mutational load and complete A3G inhibition 
by Vif and other cellular factors lies a level of activity with the potential to favor drug 
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resistance, immune escape and viral fitness. Given the demonstrated ability of HIV to 
adapt to its host, it would be surprising if adaptations deriving benefit from some level of 
A3G activity have not occurred. 
Conclusions 
Figure I illustrates the various topics discussed herein with respect to the dual ro le 
of A3G in aiding the host or virus. As shown, there are clear instances when HIV can take 
advantage of A3G induced mutation across a range of activity levels. Low mutation rates 
do not inactivate the viral genome and may in fact contribute to both drug resistance and 
immune escape. Conversely, HIV genomes suffering high mutation rates may be fil tered 
out during viral replication to favor vi ral progeny with better fi tness. Therefore, an 
ominous picture emerges wherein regardless of the action of A3G, HIV gradually gains 
the upper hand as a result of its fast replication rate and purify ing selection processes that 
allow it to essentially optim ize A3G mutation loads in progeny virions and better adapt to 
host defences and other selective pressures. 
On the other hand, interpretation of stud ies examining the effect of A3G on the 
drug resistance and CTL escape mutations in the HIV genome is subject to a major 
caveat. To date, studies identi fy ing CTL escape or drug resistance mutations have been 
conducted using two general approaches: fi rstly, by searching fo r such mutations in 
clinical isolates, and secondly, by analyzing mutations in cell culture infection systems 
where A3G is expressed. We suggest that these types of studies are inherently biased 
towards generating the observed results and missing the bigger picture. In the first case, 
the virus pool obtained from infected individuals will inevitably be enriched for CTL and 
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drug escape mutants as these have a replication advantage wherein virions harbouring 
CTL or drug target motifs modified by A3G in a way that supports the opposite outcome 
(i.e. enhanced CTL recognition or increased drug susceptibility) would have been 
efficiently eliminated. Therefore, A3G could potentially create new or more 
immunogenic epitopes or epitopes with increased drug susceptibility that have not yet 
been characterized. Furthermore, any suggestion that CTL escape or drug resistance is 
merely serendipitous neglects the point that a limited number of high quality escape and 
resistant epitopes are selected, as opposed to a large quantity of epitopes with low 
immune evading potential or substantial negative effects on viral fitness. H IV features a 
very economical propagation process in that the cost of having some genes manipulated is 
in-turn compensated for by a net effect favouring evasion of composite selective pressure. 
In the case of cell culture systems examining the role of A3G in generating drug 
resistance variants, the same caveat stands. That is, multiple drug resistance mutations 
have been identified and well characterized due to their prominence in patients. A3G 
induced mutations that may conversely enhance drug susceptibility have not been 
identified because of their scarcity caused by more rap id elimination. Accordingly, we 
suggest that instances where A3G may in fact bestow the upper hand upon the host by 
generating mutations that enhance CTL recognition or drug susceptibility have likely 
been underestimated because of their inevitable transience. It is probable that the pro- and 
anti-viral activities of A3G are not mutually exclusive and that, at different points 
throughout HIV infection and in different patients, both scenarios unfold. However, the 
principles of purifying selection are active at the level of individual cells and that of the 
entire host organism, which buries the evidence of maladaptive A3G imposed mutations 
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beneath an avalanche of fast replicating adapted variants. While new experimental 
approaches are required to identify the relative proportion of both categories of A3G 
induced mutations in an unbiased manner, the final outcome following multiple selection 
processes will determine the global impact of A3G mutations. Even if thousands of A3G 
induced mutations favouring the host occur for a single mutation that favours HIV, the 
net advantage will be to HIV as long as one favourable mutation becomes incorporated 
into the circulating viral pool. Thus, the overall context within which A3G acts is 
probably just as relevant as the ratio of pro- versus anti-viral mutations. Resolution of this 
bigger picture will be critical in order to guide future therapeutic strategies centered on 
altering A3G activity. 
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Figure 1. The complexities of the pro- and anti-HIV actions of APOBEC3G. Cross section into the 
cytoplasm of an in fected CD4+ T cell is shown, with A3G (yellow) bound to the minus strand ssDNA of 
the viral genome (white). Virus is shown as green ( fi t virus) or red (unfit virus) ci rcles forming within and 
budding out of the infected T cell. Each viral particle contains two copies of the RNA genome and mu ltiple 
copies of A3G (rods). On the outside of the in fected T cell , a cytotoxic CD8+ T cell (CTL) is shown 
recognizing a viral epitope in the context of MHC class I on the surface of the infected T cell. Arrows 
depict several possible outcomes of A3G action: ( I) the classic mode of A3G action as an innate host 
defense agent whereby it generates mutations in the viral genome resul ting in less ti t or deactivated virions 
(red); (2) some low level mutations by A3G that may result in the production of more fit virions (green); (3) 
A3G may induce mutations in the vi ral genome that resu lt in drug resistance, as shown by the emergence of 
more fi t virions (green) through the pool of cytoplasmic drug (yellow dots); (4) the process of purifying 
selection wherein a heavy mutation load on the viral genome is fil tered out throughout various stages in the 
viral li fe-cycle, resul ting in selection for a final pool of viruses with low level mutations that may enhance 
viral fi tness; (5) the mutations generated by A3G may result in the al teration ofMHC class !-restricted viral 
peptide epitopes such that recognition by CTL is abrogated (A3G-mutated CTL escape epitopes that result 
in the cloaking of the in fected cell from the CTL response are shown in green while wi ld-type CTL epitopes 
that result in the recognition and ki lling of the infected cell are shown in red); (6) the virion infectivity 
factor (Vit) of HI V (purple) binds cytoplasmic A3G marki ng it for degradation; and (7) cytoplasmic A3G is 
trapped in high-molecular-mass (HMM) ribonuclear complexes and consequently rendered ineffective. 
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Abstract 
Through their constitutive expression in cell types targeted by human immunodeficiency 
virus (HTV) and non-specific editing of DNA, the deoxycytidine deaminates APOBEC3G 
(A3G) and APOBEC3F (A3F) have been considered agents of innate immunity. Recent 
bioinformatic and mouse model studies have hinted that HIV mutations mediated by these 
enzymes can potentially enhance or diminish adaptive immunity. However, their impact 
on the adaptive immune response within HIV infected individuals has not been evaluated. 
We studied ex vivo activation of CD8+ T cells from HTV -infected individuals by HTV 
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peptide epitopes bearing A3G/F mutations. We found that A3G/F mutations within 
epitopes selectively dimin ished the CD8+ T cell response. This effect was more 
pronounced for epitopes restricted to HLA alleles associated with slower disease 
progression (due to their propensity for presentation of immunodominant CTL epitopes). 
If this observation reflects an appreciable in vivo effect, it indicates the adaptation by HIV 
to enrich A3G/F mutational hotspots in portions of its genome that encode highly 
immunogenic CTL epitopes would favor viral escape. Indeed, we found the most 
frequently mutated A3G motif (CCC) is enriched up to 6-fold with in viral genom ic 
sequences encoding immunodominant epitopes from Gag, Pol and Nef. Within each 
gene, A3G/F hotspots are more abundant in sequences encoding epitopes restricted to 
HLA alleles that present immunodominant epitopes and are common. Thus, A3G/F 
mutation of HTV mediates CTL escape in a manner more pronounced for the most 
immunogenic epitopes, as reflected in adaptation of the viral genome. 
Introduction: 
APOBEC3G (A3G) and APOBEC3F (A3F) mutate deoxycytidine (dC) to 
deoxyuridine (dU) in the reverse transcribed nascent DNA of human immunodeficiency 
virus (HTV) [ 1-5]. These host restriction factors have classical ly been considered innate 
immune agents because they act indiscriminately on cytoplasmic single-stranded DNA 
and are constitutively expressed in CD4+ T lymphocytes, macrophages, and dendritic 
cells [6-12]. A3G/F deaminate dC in trinucleotide mutational hotspots (CCC and less 
often TCC for A3G; TTC for A3F) in the minus strand registering as deoxyguanosine 
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(dG) to deoxyadenosine (dA) substitutions in the plus strand DNA potentially alter 
reading frames, terminate translation, and produce mutated proteins [ 13-17]. 
In the physiological situation, the effectiveness of A3G/F is restricted due to 
several factors. Firstly, the HIV auxiliary protein viral infectivity factor (Vif) binds and 
targets A3G/F for degradation [ 18-2 1]. Secondly, entrapment of A3G/F in high molecular 
mass (HMM) ribonuclear complexes inactivates them [22-25]. Thirdly, mutation levels in 
synthesized virions appear to be actively reduced as highly mutated genomes are 
eliminated at successive stages of viral replicat ion [26]. Thus, the majority of viral 
genomes subject to A3G/F activity suffer sublethal mutation loads. 
Adaptive responses in the form of anti-viral antibodies and cytotoxic T cells 
(CTL) follow innate immunity to contain viral propagation [27]. Robust anti-viral CTL 
responses occur in patients exhibiting slower disease progression and lower viremia [28-
33]. Mutations in CTL recognition epitopes of HIV favour immune evasion by reducing 
CTL activation [34-40]. A3G/F are intrinsic anti-viral barriers that may function early in 
infection. Once the CTL response escalates to effective levels, A3G/F action may actual ly 
aid HIV by mutating its CTL epitopes towards immune evasion [4 1, 42] . 
One study found approximately a third of rapid ly diversifying regions of HIV 
mediating CTL escape were embedded in A3G hotspots, with more highly mutating sites 
being relatively enriched in A3G hotspots [42]. Sequenced viral genomes derived from 
infected individuals are inherently biased towards displaying escape mutations because 
those that enhance CTL recognition are eliminated. Therefore, it remains unclear whether 
A3G/F mutations within CTL epitopes can equally enhance the CTL response.· A second 
study measured the response of MHC-matched CTL clones bearing transgenic peptide-
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specific T cell receptors (TCR) to peripheral blood mononuclear cells (PBMCs) infected 
by HIV produced in A3G-expressing or deficient cells. A3G mutations enhanced the CTL 
response through the introduction of stop codons resulting in truncated proteins [43]. 
Although this study indicates that A3G can modulate the CTL response in principle, the 
use of peptide-specific CTL clones may not reflect the in vivo scenario where specific 
CTLs are diverse and relatively scarce. 
We sought to address the role of A3G/F in modulating adaptive immunity in HIV-
infected individuals with the hypothesis that low-level mutations by A3G/F modify CTL 
recognition epitopes in vivo. We considered A3G/F mutations in CTL epitopes throughout 
the HIV genome and measured their effect on recognition by CD8+ T cells from HIV-
infected individuals with appropriate HLA. We report that CTL activity is generally 
diminished by A3G/F-induced mutations and that this effect varies with epitope 
immunogenicity. In silica analysis revealed greatest enrichment of A3G/F hotspot motifs 
in more immunogenic CTL epitopes. Our data suggest that A3G/F mutations primari ly 
lead to CTL-escape and that HJV has evolved strategically-placed A3G/F hotspots to 
maximize this effect. 
Material and Methods 
In Silico demarcation and simulation of A3G/A3F hotspot mutations in CTL 
epitopes. 
The 9229 nucleotide-long, plus-sense strand of HIV isolate BRU was retrieved 
from the National Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.ie). Isolate BRU was selected due to its representation of clade B HTV, 
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which is most prevalent in western countries [ 44]. Portions of the HIV genome encoding 
CTL epitopes were identified using the HIV Molecular Immuno logy Database 
(http://www.hiv.lanl.gov/content/ immunology/tables/ctl summary.html).A3G/F mutations 
on the 5' dG hotspots in the CTL epitope-coding genomic DNA were simulated and 
translated to generate mutated epitopes using DNASTAR software (DNASTAR, Madison, 
WA). For epitopes with multiple mutational hotspots or those w ith potential for the 
generation of novel hotspots, as a result of a first-round mutation on an existing hotspot, 
multiple mutant (mut) versions were considered. Wild-type (wt) and mutant (mut) forms 
of a ll selected epitopes were synthesized and used at 90% purity (Peptide 2.0 Inc., 
Chantilly, VA). 
Measurement of CTL Response 
HIV -infected study participants were recruited through the Newfoundland and 
Labrador Provinc ia l HIV C linic in St. John's, Newfoundland, and selected on the basis of 
their HLA c lass I types. Cryopreserved PBMC served as responder CD8+ T cells from 
HLA-matched patients. The ELISPOT assay used to measure the freq uency of HIV-
specific CD8+ T cells was described elsewhere [45]. Briefly, 2 x I 05 PBMC and 0.1 ).lg/ml 
peptide were added to duplicate wells for each PBMC:peptide combination and the plates 
were incubated overnight. PBMC were stim ulated w ith 5 ).lg/mL phytohemagluttin in (MP 
Biomedical, Solon, OH) as a positive control or incubated in medium alone as a negative 
control. Plates were incubated for 18-22 hours at 37° C, the ce lls were removed and I 00 
).!1/we ll of I : I 000 dilution of biotinylated IFN- y Ab (Mabtech, F lorence, Ita ly) was added 
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at room temperature for 2 hours. This was followed by I 00 f!l /well of I: I 000 dilution of 
streptavidin-alkaline phosphatase (Mabtech, Florence, Italy) . After I hour incubation, I 00 
f!llwell of chromogenic AP substrate was added for 30 minutes at room temperature. TFN-
y spot forming cells (SFC) were counted the following day using an Immunoscan Reader 
(Cellular Technology Limited, Shaker Heights, OH). The average of duplicate wells was 
obtained and the number of background spots in the negative control well subtracted. The 
total number of SFC in each well was expressed as IFN- y SFC extrapolated to SFC/ I 06 
PBMC tested. Even though the background frequency of IFN-producing un-stimulated 
CTL was negligible (typically < I 0 in I 06 PBMC), we only considered a frequencies of 
>50 SFC/1 06 PBMC as positive responses. In all, 77 subjects were tested and 27 had 
positive responses. 
In silico analysis of A3G/F hotspot frequencies in CTL epitopes 
The number of hotspots (for A3G: GGG, GGT or GGA; for A3F: GAA) inside vs. 
outside CTL epitopes in each HIV gene was determined by scanning the retrieved BRU 
sequence. The frequencies of hotspot occurrence were normalized to the number of total 
nucleotides. This frequency was calculated both for all A3G/F hotspots and only for the 
most frequently targeted A3G hotspot (GGG). Subsequently, the ratio (R) of hotspot 
frequency inside to outside epitopes was calculated for each gene. In order to evaluate 
differences in R between various genes, an index was generated by determining the 
average of the R of all genes and dividing the R of each gene by that average. Thus, an 
index of > I indicates an above average ratio of A3G/F hotspots inside to outside CTL 
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epitopes. We further conducted the same type of analysis within each gene in order to 
compare hotspot frequencies between epitopes restricted to different HLA alleles (A I, A2, 
A3, A II , A24, 87, 88, 835, 840, 844, 853, 857). 
Statistical Analysis 
Bar graphs showing SFC frequencies represent the average of duplicate tests. 
Frequencies of responding cells are expressed as spot-forming cells (SFC) per million 
PBMC (after subtracting background spots in negative control wells). ELISPOT 
responses of HTV -infected individuals that are more than two fold above those of negative 
control wells are considered as positive responses. Also, a cutoff value of 50 SFC/J 06 
PBMC is considered as positive response for ELISPOT assay, which is based on spot 
frequencies greater than 2 SD above the mean [70]. 
Results 
Demarcation of A3G/F hotspots within genomic sequences of CTL epitopes and 
simulation of A3G/F-induced mutations 
To test the hypothesis that A3G/F-mediated mutations modulate CDS+ T cell CTL 
recognition in HTV infected individuals, we examined CTL epitopes in all HTV proteins 
using the experimentally-verified HTV molecular immunology database (http://www.hiv. 
Lnl.gov/content/ immunology/tables/ctl_summary.html) as shown in Figure I (see also 
Supplementary Figures I and 2) . We analyzed a number of epitopes restricted to HLA-
A2, 844, 857 and 835. Strong CTL responses to 857-restricted and to a lesser degree B-
35 restricted epitopes correlate inversely with disease progression wh ilst 8 35 is 
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associated with rapid disease progression [46-57] . A2 and B44 are common in the 
population and present numerous HIV epitopes [28, 58] . We examined CTL epitopes in 
Gag, Pol and Nef, which comprise the most prominently recognized HIV proteins [59-
61 ]. Of257 epitopes in the database restricted to these HLA types, the genomic sequences 
of 123 were identifiable in BRU (Supplementary Figure 2). Of these, 98 epitopes (80%) 
contained :::=: I A3G/F hotspot in which A3G/F mutations were simulated and translated in 
silica. Epitopes for which the only possible mutation led to a stop codon or non-
conservative changes in HLA anchor residues were excluded. Using these criteria, we 
selected 27 wild-type (wt) epitopes and synthesized 64 derivative mutants there of (Table 
1). Of these, 7 contained a single A3G or A3F hotspot yielding I mut each (example 
shown in Figure 2-A). The other 20 yielded multiple muts, either because they contained 
> I A3G/F hotspot (multiple hotspots separated by > 3 nucleotides and were considered 
independently; example shown in Figure 2-B) or because from the initial A3G/F mutation 
a new hotspot arose that could be a A3G/F substrate in the same or subsequent round(s) of 
viral replication (example shown in Figure 2-C). Considering these possibilities, an 
epitope can potentially yield a large number of muts. For instance, an epitope containing 
the hexanucleotide GGGGAA yielded 24 possible muts. The selected wt and mut epitopes 
thus considered (Table I) were synthesized and used to evaluate the HIV -specific CD8+ T 
cell responses ofHLA-matched patients by ELISPOT. 
so 
A3G/F-simulated mutations diminish CTL recognition of HLA-B57-restricted 
epitopes 
We examined the frequency of IFN-y producing CD8+ T cells of HLA matched 
HTV infected individuals against 3 wt epitopes in Gag. Among Gag epitopes restricted to 
HLA-857, TSTLQEQIGW and I mut were tested in 5 HLA-857+ subjects (P7, P45, P7 1, 
Pl66, Pl97). Of these, only P197 responded, showing a 3-fold higher response to wt 
over the mut (280 vs. 85 SFC/ 1 0\ (Figure 3-A). KAFSPEVIP and I mut were tested in 
the same 5 subjects (P7, P45, P71 , P 166, P 197); three (P71, P 166, P 197) responded to the 
wt (P71 : 397, Pl66: 50, Pl97: 90 SFC/ 106) , while none responded to the mut (Figure 3-
8). AISPRTLNAW and I mut were examined in 8 patients (P7, P20, P45, P71, P76, 
P 166, P 185, P 197), of which 4 (P7, P71 , P 166, P 197) responded ; P71 and P 197 exhibited 
responses to wt that were 3.27- and 1.4-fold higher than the mut, respectively (P71 : 895 
vs. 273; Pl97: 160 vs. 112 SFC/106 P8MC); P7 and Pl 66 responded only to wt (P7: 815 ; 
Pl 66: 386 SFC/ 1 06 P8MC), (Figure 3-C). The wt Nef epitope GPGVRYPLTFGWCY and 
7 muts were tested in 6 patients (P20, P45, P68, P76, P 166, P 185); only P68 responded 
and only to the wt (180 SFC/ 1 06 PBMC), (Figure 3-0). The wt Pol epitope 
PIVLPEKDSW and I mut were tested in 2 patients but did not induce a response. Taken 
together, 9 patients responded only to wt epitopes wh ile 3 responded to both wt and mut, 
for which the response to wt epitopes was 1.4- to 3-fold higher. 
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A3G/F-simulated mutations diminish CTL recognition of HLA-A2-restricted 
epitopes 
We examined 2 types of HLA-A2-restricted epitopes of Gag. Among them, 
FLGKIWPS and 3 muts were tested in 9 patients (P3, P 18, P30, P35, P64, P71 , P78, P98, 
P234), ofwhich 5 responded and only to wt (P3: 152; P64: 88; P71: 60; P78: 85; P98: 
142 SFC/ 1 06), (Figure 4-A); YVDRFYKTL and I mut were tested in I 0 patients but none 
responded. 2 Nef epitopes were examined. The immunodominant FLKEKGGLEGL 
epitope and 15 muts were tested in 30 patients, of which 4 responded to wt (P62: 72; 
P201: 1145; P211: 151 2; P213 : 231; P213': 390 SFC/ 106 PBMC); ofthese, I patient 
responded to a single mutant with a 40% response, relative to that of wt (P211: 151 2 vs. 
910 SFC/ 1 06 PBMC), (Figure 4-B to E). The Nef epitopes VLEWRFDSRL and 
PLTFGWCYKLV, each with I mut, were tested in I 0 and 13 patients respectively, but no 
response was detected. 9 Pol epitopes were tested and 4 induced a response. 
IYQYMDDLYV and I mut elicited a relatively comparable response; however, unlike 
most muts that harbor non-conservative alterations, A3G/F action on th is epitope induces 
a conservative M to I mutation. This epitope was tested in 20 different patients, of which 
3 responded (for wt vs. mut: P35 : 147 vs. 92; P35 ': 190 vs. 160; P2 14: 225 vs. 90; P233 : 
570 vs. 495 SFC/ 1 06 PBMC), (Figure 4-F); ILKEPVHGV and I mut were tested in 17 
patients, out of which 3 responded comparably to wt and mut (for wt vs. mut: P35: 2675 
vs. 2442; P35': 1380 vs. 1305; P71 : 90 vs. 88; PI05 : 305 vs. 405 SFC/106 PBMC), 
(Figure 3-G). LVGPTPVNII with I mut were tested in 8 patients, out of which 2 
responded only to wt (P11 7: 62; P2 14: 300 SFC/ Ix l06 PBMC), (Figure 4-H); 
ALVEICTEM and I mut were tested in II patients and on ly elicited a response to wt in I 
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(P43: 157 SFC/ 1 06 PBMC), (Figure 4-I). 5 other Pol epitopes (LLWKGEGAV, 
VIYQYMDDL, VLVGPTPVNJ, LLRWGLTTPDKK and VLDVGDAYFSV) and muts 
thereof did not produce a response in 38 patients. Altogether, for the 6 A2-restricted 
epitopes of Gag, Nef and Pol that induced responses, 4 induced a greater response in wt 
whilst 2 induced a comparable response in wt and muts in all patients. Thus, A3G/F-
induced mutations in A2-restricted epitopes diminished the CTL response in 67% and did 
not affect the response in 33% of cases. 
A3G/F-simulated mutations reduce the CTL response to the majority of HLA-B44-
restricted epitopes 
Two 844-restricted epitopes in Gag were examined. Among them, LSEGATPQDL 
and 3 muts were tested in 16 patients, ofwhich 5 responded to wt (P35 : 4245; P57: 7 12; 
P67: 775 ; P133: 1137; P242: 610 SFC/ 106 PBMC). Amongst these, 2 responded to muts 
(P35: 3645 ; P57: 192 SFC/ 1 06 P8MC to G toR mut), (Figure 5-A); RDYVDRFYKTL 
and I mut were tested in 6 patients but no response was detected. The Nef epitope 
KEKGGLEGL and 5 muts were tested in 5 patients (P55, P67, P I 03, P 118, P2 1 0), 4 of 
which responded to wt only (P55: 3 12; P67: 62; PI 03: 705; Pll8: 240 SFC/ 1 06 PBMC), 
(Figure 5-8). Overall , 9 patients responded to 2 types of epitopes restricted to 844. Of 
these, 7 responded only to wt whilst 2 responded to both wt and mut and in a ll cases, the 
response to wt was greater. 
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Analysis of A3G/F hotspot frequency inside CTL epitopes 
The ex vivo reduction of CTL response by A3G/F mutations suggests that HIV 
would adapt to maximize A3G/F hotspots in CTL epitopes, and that A3G/F hotspots may 
be more frequent in more immunogenic or broadly presented epitopes. To test this 
hypothesis, we compared the ratio (R value) of A3G/F hotspot frequency inside to outside 
CTL epitopes between different HIV genes, after normal iz ing them for sequence length. 
We considered the frequencies of al l A3G/F hotspots. Because A3G mutates HTV - I 0-
fold more potently than A3F and GGG is its preferentially targeted hotspot [ 13, 24, 62, 
63], we also considered the frequency of GGG independently (Table 2). Relative 
enrichment of hotspots inside vs. outside CTL motifs for each gene is defined by an index 
of the R value of each gene to relative the average R. Considering the index values for all 
hotspots, as well as GGG alone, Gag, Pol and Nef exhibi ted the highest indices compared 
to other genes (for GGG: 1.3, 2.1 and 2.0; for all hostpots: 1.3, 1.4 and 1.1 , respectively), 
(Figure 6-A). 
We next addressed the suggestion that enrichment of A3G/F hotspots amongst 
various epitopes in each gene correlates with immunogenici ty as defined by the 
commonness of its recognition by CTL. We divided the epitopes on the basis of their 
restricting HLA (A I, A2, A3 , A II , A24, 87, B8, 835, B44, 857). For each gene, we 
quantitated hotspots inside vs. outside epitopes restricted to individual HLA al leles. The 
pattern of hotspot enrichment with respect to HLA-restriction was not consistent amongst 
genes (Figure 6-b). However, for genes with the most experimentally verified CTL 
epitopes (Gag, Pol, Env, Net), the indices for HLA-857 were > I, with GGG being over-
represented by 1.7- to 4.9-fold. In contrast, the frequency ofGGG motifs in HLA-835 is 
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>2-fold lower than that of other HLA-8 alleles. The most striking enrichment was 
observed in Nef, where all A3G/F hotspots and GGG were respectively 5.7-, 17.6-fold 
enriched in 844-restricted as compared to 835-restricted epitopes. Nef conta ins a single 
844-restricted epitope that induces robust CTL responses in a broad portion of the 
population [28] . We noted that its coding sequence contains a GAA tract, a GGGGGA 
tract, a GGAA tract and a GGA tract, providing 9 hotspots for first round mutations by 
A3G/F and >20 muts considering multiple replication rounds. We also noted a higher 
frequency of GGG motifs in A3-restricted epitopes of Gag and Pol (2.1- to 2 .3-fold 
enriched over epitopes restricted to other HLAs). These results may reflect the higher 
number of CTL epitopes in these gene segments in combination w ith the prevalence of 
the A3 allele in the population. 
In order to test if there is selective A3G/F hotspot enrichment within CTL 
epitopes, we considered antibody recognition epitopes within Env as a control. We 
compared the R values of A3G/F hotspots inside to outside CTL epitopes of each gene to 
the R value of hotspots inside to outs ide antibody recogni tion epitopes in Env. The R 
value for antibody epitopes in Env is 0.71 and 0.9 for all A3G/F hotspots and GGG, 
respectively. These are 1.3- to 3-fold lower than the R values for CTL epitopes of Pol 
( 1.06, 1.63), Gag ( 1.1 6, 2.60) and Nef (0.89, 2.45), but up to 7-fold higher than the R 
values found in the CTL motifs of other HIV genes (Vif, Vpr, Tat, Rev,Vpu). The 
average R value of GGG inside to outs ide CTL epitopes in all genes is 2-fold higher than 
its counterpart for Ab epitopes across all genes (Figure 6-c). Collectively, this analysis 
reveals two levels of enrichment in A3G/F hotspots that is of sign ificant for adaptive 
immunity: first, enrichment w ithin CTL epitopes of Gag, Pol and N ef, and second, 
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relative enrichment in epitopes within each gene restricted to HLAs that present more 
immunogenic epitopes at an individual or population level. 
Discussion 
The character of the anti-HIV CTL response plays a key role in controlling 
viremia as evidenced by the fact that susceptibility to disease progression is associated 
with variations in an HIV-infected individual 's class I HLA genotype [46, 4S, 64-67]. 
A3G induced mutations that generate truncated peptides have the potential to improve the 
CTL response against HIV-infected cells in vitro [43]. ln contrast, another study proposed 
that A3G hotspots in CTL escape sites can result in the reduction of CTL response [42]. 
Our research indicates that A3G/F may in fact benefit HTV by contributing to drug 
resistance and other contextual fi tness-inducing mutations [41 , 68]. We reasoned that the 
role of A3G/F in the CTL response is also likely to include both pro- and anti-viral 
outcomes at different times during HlV infection. We hypothesized that A3G/F may be 
able to mediate mutations in CTL epitopes that strengthen immune recognition, but that 
this activity goes unobserved due to the rapid elimination of viral genomes harboring 
these mutations. Instead, this anti-viral role of A3G/F may reveal itse lf by examining 
patients' CTL response to A3G/F-mutated CTL epitopes, as some CTL would have likely 
differentiated into rare, but lingering memory cells. We show that A3G/F mutations can 
indeed modulate adaptive immunity in HIV -infected individuals by decreasing CDS+ T 
cell recognition of common CTL epitopes. The response of CDS+ T cells from HLA-
matched HIV -infected individuals was almost always reduced as a result of A3G/F 
mutations in epitopes restricted to A2, B44, and B57 HLA alleles. ln order to ascertain 
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whether this trend was a product of our experimental procedures, we tested several 
epitopes and muts thereof that are restricted to HLA-B35. Interestingly, we found that for 
HLA-B35, which associates with rapid disease progression, A3G/F mutated epitopes 
enhanced the CTL response (Supplementary Figure 3). 
Previous studies of the CD8+ T cell response in HIV -infected cohorts to epitope 
variants adapted at the population level found that more than half of the muts retained 
their ability to stimulate CD8+ T cells [29]. Because some of the epitopes we tested were 
hypothetical variants, our observation that A3G/F-induced mutations specifically alter 
CTL epitopes so as to diminish CTL recognition is unlikely to be due enti rely to 
simulating mutations in silica. Instead, our observations can be explained by the fact that 
the majority of A3G/F -induced mutations are non-conservative and are thus I ikely to 
change the epitope conformation. Alternatively, CTL recognition of A3G/F hotspot-
containing epitopes may be less tolerant of mutations compared to other epitopes. Either 
possibility suggests that the viral genome has evolved to place and/or maintain A3G/F 
hotpots in positions that exploit A3G/F activity to escape CTL. This is also supported by 
our observation of A3G/F hotspot enrichment inside genomic sequences that encode CTL 
epitopes. Within each HIV gene, A3G/F hotspots were enriched in sequences encoding 
epitopes restricted to common HLA alleles or HLA alleles that present more 
immunogen ic epitopes and were conversely underrepresented in HLA alleles that do not 
present immunodominant epitopes. This finding further supports a model where the CTL 
response at the population level is an appreciable force in directing the evolution of 
A3G/F hotspot placement throughout the viral genome. Indeed, had we observed the 
opposite, that A3G/F-mutated epitopes elicit a higher or even simi lar CTL response in 
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immunogenic epitopes, it would have suggested that the viral genome lacks sufficient 
plasticity to adapt to utilize A3G/F to escape CTL, or that the CTL response is not a 
crucial determinant of viral genome evolution. 
Several non-mutually exclusive mechanisms can explain the reduction of CTL 
response as a result of A3G/F mutations. First, it may be caused by decreased availability 
of mut epitopes due to elimination of viral genomes harboring A3G/F mutations or the 
ineffectiveness of A3G/F action in vivo. Second, it is possible that some simulated A3G/F 
mutations did not occur in tested patients or that they were short-lived because they were 
rapidly replaced by other mutations that increased fi tness in the face of stronger non-CTL 
pressures (e.g. drug treatment). These possibilities are counteracted by frequent detection 
of mutations at A3G/F hotspots within sequenced viral genomes from HIV -infected 
individuals. Even if the occurrence of the mutation elicited a response in as low as ~ I in 
10,000 CDS+ T cells, it should be detectable by ELI SPOT. Furthermore, our observation 
that A3G/F muts enhanced the response to several epitopes (e.g. B-35 restricted epitopes) 
argues against these being the sole mechanisms. Third, it is possible that there are in fact 
CTL that would respond to the mut epitope, but that their frequency is below the limit of 
detection by ELISPOT (~ 1 in 10,000 CTL). Ifthis is the case, a revised assay including 
longer incubations and different culture conditions that stimulate for the expansion of 
these rare CTLs should reveal responder CTL specific for muts. Finally, it is possible that 
our observations are not due to the lack of A3G/F-mutated epitopes or responder CTL, 
but that indeed A3G/F mutates epitopes with the specific outcome of diminishing the CTL 
response. Several lines of evidence support this model. First, we excluded A3G/F 
mutations that may affect HLA-binding anchor residues in epitopes so that our 
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observations cannot be explained entirely by failure of epitope presentation. Second, we 
showed that it is possible for A3G/F mutation to enhance CTL recognition in our 
experimental system. Third, our in silica analysis has revealed selective enrichment of 
A3G/F hotspots in immunogenic CTL with a HLA association, suggesting that our 
observation is reflective of an in vivo effect that is sufficiently relevant to have left its 
evolutionary footprint on the vi ral genome. 
The molecular basis for our results may be that A3G/F mutations decrease the 
affinity between the TCR/epitope/MHC complex. Alternatively, a distinct CTL pool may 
recognize mut epitopes less avidly. Whatever the case may be, our results show that 
A3G/F mutations can play a role in adaptive immunity against HIV by diminish ing the 
CTL response. This contrasts a recent report that A3G mutations promote the CTL 
response through introducing premature stop codons leading to the generation of 
truncated proteins [43] . Although this study demonstrated the potential of A3G/F to 
generate more immunogenic epitopes through an indirect mechanism, we report here that 
the opposite occurs in HTV -infected individuals thorough the direct action of A3G/F on 
CD8+ T cell epitopes. ln said study, an in vitro infection system was utilized with Vif+ or 
Vif- virus and CTL clones bearing transgenic receptors, while our study probed the CTL 
response of PBMC obtained from HTV infected individuals. Our results may be more 
reflective of the physiological setting that accounts for the diversity of individual patients 
with respect to differences in HLA make up, infect ion and drug treatment stages. 
A recent study shows that the generation of "neo-epitopes", possibly to act as CTL 
decoys, is a strategy for viral escape from the host immune system [69]. Nef has been 
shown to frequentl y dep loy decoy epitopes, possibly because it is less important fo r the 
59 
viral life cycle and hence more tolerant of mutations. HLA-A24 is a frequent presenter of 
these decoy epitopes and we note that interestingly, the high response to A3G/F -mutated 
835 restricted epitopes was observed in patients who also carried the A24 allele. Thus, it 
is possible that mutations in 835-restricted epitopes enhance their immunogenicity when 
presented by A24. Alternatively, since CTL responses to 835-restriced epitopes have 
been shown to not be as effective as responses to epitopes presented by 857 and other 
HLAs in combating viral loads, our observation may represent a role for A3G/F in the 
generation of decoy epitopes, in addition to its role in suppressing the recognition of 
immunodominant epitopes. Further work is required to shed light on the ful l role of 
A3G/F on the CTL response, as well as on the molecular and cellular pathways through 
which these DNA-mutating enzymes influence adaptive immunity. 
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Figure 1. Delineation of the amino acid and DNA sequences of CTL epitopes. 
Panels A, B and C show the locations of CTL epitopes in the Pol, Gag and Nef 
polypeptides respectively of HIV -1 BRU isolate. The brackets indicate epitopes on the 
peptide sequence. Epitopes restricted to different HLA alleles are shown in different 
colors and the restricting HLA is indicated above the bracket. Broken lines display 
epitopes with no A3G/F hotspots and continuous lines show epitopes that harbor A3G/F 
hotspots. Panels D, E and F show the location of the viral genomic sequences that 
encode CTL epitopes in Pol, Gag and Nef, respectively in the IUV-1 BRU isolate plus-
sense strand. Color delineates the sequences encoding CTL epitopes from the 
surrounding DNA. Colors do not otherwise correspond to any common features amongst 
genes or epitopes. 
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Figure 2. Simulation of A3G/F-mediated mutations in CTL epitopes. Wild type epitopes 
and their encoding DNA sequence are shown. The A3G/F targeting hotspots in the plus-
sense epitope encoding sequence are colored blue and underlined. The simulated A3G/F-
mediated G to A mutation in the viral genomic sequence and the resulting amino acid 
mutation in the CTL epitope are shown below in red. A. Example of an epitope with a 
single possible mutation. B. Example of an epitope with multiple independent mutations. 
Hotspots separated by >3 nucleotides were considered as independent and mutant epitopes 
bearing either mutation or combinations of multiple mutations were considered. C. 
Example of an epitope with multiple sequential mutations. For hotspots where an initial 
A3G/F-mediated mutation can generate a new A3G/F hotspot that can be acted upon in the 
same or a subsequent viral replication cycle, mutant epitopes bearing each individual 
mutation or combinations of mutations were considered. 
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Figure 3. The response of CTL from different HIV-infected individuals to HLA-B57-
restricted wild type and A3G/F -mutated epitopes. HIV-in fected individual P8MC 
response to wild type and mutant epitopes are shown on the Y -axis, as SFC (Spot Forming 
Cell) II 06 P8MC. X-axis di splays di tferent HIV infected individual s (patients) . A. 
Induction of IFN-y is compared between wi ld type and a mutant form of the 857-restriced 
Gag epitope TSTLQEQIGW in P197. B. Induction of IFN-y is compared between wi ld 
type and 2 mutant forms of the 857-restriced Gag epitope KAFSPEVIP in P7 1, P 166, 
Pl97. C. Induction ofiFN-y is compared between w ild type and a mutant fo rm of the 857-
restri ced Gag epitope AISPRTLNAW in P71 , Pl66, Pl97, P7. D. Induction of IFN-y is 
compared between wild type and 7 mutant forms of the 857 restricted Nef epitope 
GPGVRYPLTFGWCY in P68 . Asterisk indicates the responses greater than 50 SFC/ 1 06 
P8MC. 
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Figure 4. The response of CTL from different HIV infected individuals to HLA-A2-
restricted wild type and A3G/F-mutated epitopes. HLA-matched, HI V-i nfected 
indivi dua ls PBMC response to wild type and mutant epitopes are shown on theY -axis, as 
SFC (Spot Forming Cell ) 1106 PBMC. X-axis displays different HIV -in fected individua ls 
(patients). A. Induction of iFN-y is compared between wi ld type and 3 mutant fo rms of the 
HLA-A2 restricted Gag epitopes FLGKIWSPHK in P64, P98, P3 , P7 1, P78. B-E. 
Induction of IFN-y is compared between wild type and 15 mutant forms of the HLA-A2 
restricted Nef epitope FLKEKGGLEGL in P62, P20 I, P2 11 , P2 13. F. Induction of IFN-y 
is compared between wi ld type and a mutant form of the HLA-A2 restricted Pol epitope 
IYQYMDDLYV in P35, P2 14 , P233. G. Induction of IFN-y is compared between wi ld 
type and a mutant form of the HLA-A2 restricted Pol epitope ILKEPVHGV in P35, P7 1, 
P IOS . H. Induction of IFN-y is compared between wild type and a mutant fo rm of the 
HLA-A2 restricted Pol epitope LVGPTPVNII in P I I7, P2 14 . I. Induction of IFN-y is 
compared between w ild type and a mutant form of the HLA-A2 restricted Pol epitope 
ALVEICTEM in P43 . Asterisk indicates the responses greater than 50 SFC/ I06 PBMC. 
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Figure 5. The response of CTL fi'Om different HIV infected individuals to HLA-
844-restricted wild type and A3G/F-mutated epitopes. HLA matched, HJV-infected 
individuals PBMC response to wild type and mutant epitopes are shown on Y -axis, as 
SFC (Spot Forming Cell)/ 106 P8MC. X-axis displays different HIV-infected individuals 
(patients) . A. Induction of IFN-y is compared between wild type and 3 mutant forms of 
the HLA-844 restricted Gag epitope LSEGATPQDL in P35, P57, P67, P l 33, P242 . B. 
Induction of IFN-y is compared between wild type and 6 mutant forms of the HLA-844 
restricted Nefepitope KEKGGLEGL in PSS, P67, PI03 , Pll8. A response greater than 
50 SFC/106 P8MC is indicated by*. 
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Figure 6. Analyzing enrichment of A3G/F hotspot inside/outside CTL epitopes in 
HIV genes. A. For each HIV gene, the frequency of A3G/F hotspots (ei ther a ll hotspots : 
GGG, GGA, GGT, GAA, o r GGG alone) was calculated in regions that encode fo r CTL 
epi topes and regions that do not encode for CTL epitopes. Normalized frequencies were 
calculated by taking into account the total leng th of the sequence. For each HI V gene, the 
normalized frequency of A3G/F hotspots inside sequences that encode CTL moti fs was 
div ided by the no rmalized frequency of A3G/F hotspots in sequences that do not encode 
CTL epitopes to generate a Ratio (R-value). The average of R-values was determined and 
each R-value was divided by the average to obtai n the index val ue and allow for 
determination o f the relative enrichment of hotspots w ithin the CTL epitopes of each 
gene, as compared to the average ratio of hotspots ins ide to outside CTL epitopes. B. T he 
same ana lys is as pane l A was conducted ·within each HIV gene to compare the relative 
enrichment o f A3G/F hotspots in sequences that encode CTL epitopes restricted to 
diffe rent HLA all e les. C. Comparison of A3G/F enrichment in CTL epitopes vs. the 
po rtions of the Env gene that encode antibody recognition epitopes. Average R-value for 
the CTL epi topes of a ll genes (average of all R values ti·om panel A) was compared to the 
R value of A3G/F hotspots ins ide:outside sequences encoding antibody recogn ition 
mo ti fs w ithin Env. The Index value= I is shown as a scale, since an index > I indicates 
relative enri chment. 
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Table I. List of wild type and A3G/F-mutated epitopes used to measure the CTL 
response of HLA-matched, HIV-infected individuals. Wild type epi topes and their 
A3G/F-mutated versions used to test the CTL response of HLA-matched, HIY-intected 
indiv iduals by ELISPOT are shown . The polypeptide of origin for each epitope, its 
restricting HLA allele and the vi ral genomic sequence encoding the epitope in HIV -I BRU 
isolate are shown. 
.. ........ .. .. 
· · ····· ·· ··········· · ···~ · 
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Table 2. Analyzing enrichment of A3G/F hotspot inside/outside CTL epitopes in HIV 
genes. For each HIV gene, the frequency of A3G/F hotspots (ei ther al l hotspots: GGG, 
GGA, GGT, GAA, o r GGG alone) was calculated in regions that encode for CTL epi topes 
and regions that do not encode for CTL epi topes. Normalized frequencies were calculated 
by taking into account the total length of the sequence. For each l-I l Y gene, the normalized 
frequ ency of A3G/F ho tspots inside sequences that encode CTL motifs was divided by the 
normalized frequency of A3G/F hotspots in sequences that do not encode CTL epi topes to 
generate a Ratio (R-value). The average of R-values was determined and each R-value was 
divided by the average to obtain the index value and allow for determination of the relative 
enri chment o f hotspots within the CTL epitopes of each gene, as compared to the average 
ratio of hotspots inside to outs ide CTL epitopes. An index value > I indicates relative 
enrichment. 
Genes Normalized Nonnali7.cd 'onnalizcd Nonnalized Ratio of all Index Ratio Index 
number of number of number of number of hotspots value ofGGG value 
hotspots GGG hotspots GGG lnsidc:outsidc hotspots 
inside CTL· hotspots outside CTL· hotspots cpitopcs lnsidc:outsidc 
epitopcs inside CTL· cpitopes outside CTL· epitopes 
cpitopes cpitopcs 
Vpr 0.1041 0.0277 0.0884 0.0204 1.17 1.3948 1.36 1.119 
Pol 0.0924 0.023 0.0794 0.00883 1.16 1.3829 2.60 2.139 
Gag 0.0864 0.0233 0.0813 0.0143 1.06 1.2637 1.63 1.341 
Vif 0.0774 0.0202 0.0992 0.0177 0.78 0.9299 1.14 0.938 
Nef 0.0839 0.0272 0.0944 0.0111 0.889 1.0598 2.45 2.016 
Env 0.070 0.0176 0.0991 0.0226 0.706 0.8416 0.779 0.641 
Rev 0.094 0.00556 0.1345 0.0409 0.699 0.8333 0.136 0.111 
Tat 0.0363 0.00 0.1041 0.0208 0.349 0.4160 <0.291 0.239 
Vpu 0.0701 0.00 0.952 0.0317 0.736 0.8774 <0.553 0.455 
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Supplementary Figure 1. Map of all HIV-1 BRU isolate CTL epitopes across the 
viral proteome. HIV proteins are shown individually (A: Pol, B: Rev, C: Vif, D: Nef, 
E: Vpr, F: Env, G: Gag, H: Tat). The brackets indicate epitopes on the peptide sequence. 
Epitopes restricted to different HLA alleles are shown in different colors and the 
restricting HLA is indicated above the bracket Broken lines display epitopes with no 
A3G/F hotspots and continuous lines show epitopes that harbor A3G/F hotspots. 
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Supplementary Figure 2. Map of the viral genomic sequences that encode CTL epitopes in 
the HIV-1 BRU isolate plus-sense strand. The sequence of each gene is shown individually (A: 
Pol, B: Rev, C: Vif, D: Nef, E: Vpr, F: Env, G: Gag, H: Tat). Color delineates the sequences 
encoding CTL epitopes from the surrounding DNA Colors do not otherwise correspond to any 
common features amongst genes or epitopes. 
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Supplementary Figure 3. The IFN-\' response to HLA-B35-restricted epitopes harboring 
A3G/F-mediated m utations. HLA-matched, HIV-infected individuals PBMC response was 
measured by ELISPOT to wild type and mutant epitopes in Pol, Gag and Nef. X-axis displays 
different H IV infected individuals (patients). A. Induction of IFN-y is compared between the wi ld 
type form and 5 mutant versions of the Gag epitope PPIPVGEIY in PSI. B. Induction of IFN-y is 
compared between the wild type fo rm and 3 mutant versions of the Gag epitope GPGVRYPLTF in 
P82. C. Induction of IFN-y is compared between the wi ld type form and a mutant version of the 
Nef epitope YPLTFGWCY in P82, PSI', P244. D. Induction of IFN-y is compared between the 
w ild type form and a mutant version of the Pol epitope TVLDGDAY in P82. Multiple other 835-
restricted epitopes were tested but did not yield a response. Asterisk indi cates the responses greater 
than 50 SFC/ 1 06 PBMC. 
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Summary: 
Human immunodeficiency virus (HIV) utilizes our immune system to replicate in 
the body and has developed ways to overcome it. However, our immune cells have 
intrinsic barriers against HIV. An emerging set of these antiviral factors are the APOBEC 
enzymes, most notably APOBEC3G (A3G) and APOBEC3F (A3F). These cytid ine 
deaminase enzymes act by introducing C to U mutations in the negative strand ofthe viral 
genome during its replication in the cytoplasm of infected T cells. These mutations can 
lead to the degradation of viral DNA by uracil-removal pathways, or alternatively result 
in G to A mutations in the coding (positive) strand, which can inactivate the virus. 
Because they are constitutively expressed pre-infection with HIV, and act non-specifical ly 
throughout the viral DNA, APBOECS have been considered agents of the innate immune 
response. 
We hypothesized that beyond their role in innate immunity, mutations by A3G or 
A3F modulate the adaptive immune system by modifying peptide epitopes recognized by 
cytotoxic CD8+ T (CTL) cells. To test our hypothesis, we proceeded with three goals: 
I) In silica identification of all CTL epitopes for each HLA throughout the HIV 
genome 
2) Measuring the CTL responses of HIV+ patients to peptides containing A3G/F 
simulated mutations 
3) In silica analysis of A3G/F hotspot motifs inside and outside of the CTL 
epi topes. 
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Thus, we simulated A3G mutations throughout the HTV genome in silica and 
catalogued those s ituated in CTL epitopes in the context of different class l MHC 
molecules and genes. We selected 857, A2, and 844 because they are common HLA and 
the degree of CTL response to their epitopes correlates inversely w ith disease 
progression. As a control , we selected HLA-835 as it positively correlates with the 
progression of AIDS. Also, we initially selected epitopes of gag, pol and nefgenes since 
they represent prominent CTL epitopes and a strong CTL response to epitopes in gag and 
nefcorrelates with v ira l containment by the immune system. We then used synthetic A3G 
mutant peptides and their w ild-type (WT) counterparts to stimulate the CTL response in 
P8MCs of HLA-matched patients and compared the ex vivo response of CTL to peptide 
epitopes bearing A3G/F mutations with WT epitopes. Using the ELTSPOT assay, we 
found that the vast majority of mutant epitopes elicit decreased IFN-y production by CTL, 
in comparison to WT. Epitopes, inc luding WT and mutant fo rms were tested in HIV 
patients. Notably, the gap between the CTL response to the WT and mutant epitopes are 
higher among the epitopes for which a strong CTL response correlates inverse ly with 
disease progression . However, this scenario is different in the case of HLA-835 w ith a 
direct effect on disease progression . While there is no CTL response to the WT form of 
these epitopes, except in pol, the response to mutant epitopes restricted to HLA-835 
located in gag and nef is increased. Our resu lts indicate that HTV may use APOBEC 
induced mutations as a mechanism of CTL escape. Furthermore, our fi ndings suggest 
that the HIV genome may be enriched in APOBEC hotspot motifs in regions encoding fo r 
CTL epitopes. 
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To test this prediction, we compared A3G/F hotspots inside and outside CTL 
epitopes. We located A3GIF mutational hotspots in all epitopes. After normaliz ing them 
to the number of nucleotides in the different epitopes, we calculated the index number by 
determining the average of total R values of all genes or HLAs and dividing the R value 
of each gene or HLA by the average total R value. We compared the index number of 
hotspots in CTL epitopes between different genes and HLAs and found that indeed there 
are higher number of A3GIF specific motifs inside CTL epitopes versus outside them in 
gag, nef, and pol in comparison to the other viral genes. Also, A3G/F hotspots are more 
enriched inside CTL epitopes versus outside, especially in epitopes restricted to HLA-
857 rather than HLA-835. HLA types that are prevalent and immunodominant in the 
human population (HLA-844, HLA-A3), and immunodominant in terms of presentation 
of HIV epitopes, show higher hotspot enrichment compared to other HLAs. As a negative 
control, we checked the number of A3G/F hotspots inside and outs ide antibody aligned 
epitopes. There was no hotspot accumulation inside Ab epitopes. Our results indicate that 
rather than being beneficial for the adaptive immune system, mutations of the HIV 
genome by A3G and A3F may have the opposite effect by assisting HIV to escape from 
CTL responses. 
Previous studies report that CTL response is improved through A3G mutations 
leading to formation of stop codons that generate truncated proteins in cultured HIV 
infected cells. In contrast, we report here that direct action of A3G/F on CTL epitopes 
have reverse effect in HIV-infected individuals. Also, another study indicates the role of 
"neo-epitopes" as CTL decoys, which is an approach for vi ral escape from the host 
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immune system. "Neo-epitopes" are primarily restricted to HLA-A24 epitopes located in 
Nef. This is consistent with our data showing an improved CTL response to A3G/F-
mutated HLA-B35 restricted epitopes in patients with HLA-A24. Thus, our data may 
reflect the effect of A3G/F in both suppressing the recognition of immunodominant 
epitopes and the generation of decoy epitopes. Further investigation is needed to gain 
better insight into the mechanisms underlying the differences in CTL response between 
WT and mutant epitopes. Uncovering the role of specific subsets of CTLs (e.g. memory T 
cells) will aid in elucidating this mechanism. It will also be essential to understand how 
A3G/F induced mutations affect CTL response through studying the downstream 
molecular and cellular signaling pathways. 
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